In brief
- The NIDA (National Institute on Drug Abuse) has awarded a grant of up to $11 million to Brigham and Women’s Hospital in Boston to research ibogaine for opioid addiction.
- The protocol sets the toxicity threshold at a QTc interval exceeding 500 milliseconds or a 20% increase, with continuous cardiac monitoring throughout the hospital stay.
- The second phase will recruit individuals with opioid addiction who do not respond well to buprenorphine.
The U.S. National Institute on Drug Abuse (NIDA) has awarded Brigham and Women’s Hospital in Boston a grant of up to $11 million to investigate whether ibogaine can be safely administered to people with opioid addiction. The cooperative agreement, identified as UG3DA064414, releases an initial $2,288,947 and runs from June 2026 to May 2028. It is led by psychiatrist Joji Suzuki of Mass General Brigham.
A design built around the heart
Ibogaine, extracted from the root bark of the African iboga shrub, can prolong the heart’s QT interval, which in some cases has led to severe arrhythmias. Suzuki’s protocol addresses this risk directly: it classifies a dose as excessively toxic if a participant’s QTc interval exceeds 500 milliseconds or increases by 20% from their baseline value. All administration will take place during a hospital stay with continuous electrocardiogram monitoring—the same level of surveillance applied to drugs like sotalol or dofetilide, which are used to treat cardiac arrhythmias.
Two phases: first the safe dose, then efficacy
The first phase will administer single, escalating doses of pharmaceutical-grade ibogaine to healthy volunteers, with the goal of identifying the maximum tolerable dose. If results permit, a second phase (2a) will recruit people with opioid addiction who have not responded adequately to buprenorphine, compare different doses with blinded evaluators, and only include participants who have never tried ibogaine. Ibogaine remains classified as a Schedule I substance in the United States, and there is no FDA-approved form; in April, the agency had already authorized a first study with noribogaine, ibogaine’s main metabolite, for alcohol use disorder—a different and more advanced path than the one now opened by this Brigham and Women’s Hospital trial.
What this implies
The researchers state they are not aware of any other rigorous trial, authorized by the FDA as an investigational drug, that tests ibogaine itself for opioid addiction, at a time when there is also another federal path open through ARPA-H and state programs underway in Arizona. A recent editorial in the Journal of Addiction Medicine warned that some advocates present ibogaine as a substitute, rather than a complement, to medications that reduce the risk of overdose death; stopping methadone or buprenorphine for an unproven therapy could increase that risk, according to the authors. The trial’s own design, focused on quantifying cardiac risk before testing any therapeutic effect, reflects how little is still known about the safety of ibogaine at the doses necessary to treat addictions, compared to clinics in countries like Mexico, where the treatment is offered today for about $8,000 without this type of clinical control.
Source
- Joseph James. NIH Funds Boston Ibogaine Study for Opioid Addiction with Strict Heart Rhythm Limits Built into Its Design. Medical Daily, September 22, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
